| This week's sponsor is ExL Events. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, April 16, 2018 Merck's Keytruda-chemo combo is already approved in first-line lung cancer based on phase 2 data, but that FDA nod requires backup from a larger phase 3 trial—and doctors and investors have worried the data wouldn't measure up. They don't have to worry anymore. |
|
|
Top Stories Of The Week Wednesday, April 18, 2018 Emma Walmsley continues her R&D metamorphosis at GlaxoSmithKline with another big new hire in the guise of Kevin Sin, an ex-Genentech executive who will be seeking out new pipeline plays for the U.K.’s largest drugmaker. Thursday, April 19, 2018 That was fast. Just a few hours after Allergan confirmed that it was in buyout talks for hot target Shire, it said it didn’t intend to make an offer. Tuesday, April 17, 2018 A combination of Checkmate's toll-like receptor 9 agonist and Merck's Keytruda reversed PD-1 resistance in advanced melanoma patients who had not responded to previous anti-PD-1 treatments. Tuesday, April 17, 2018 Amazon's plan to jump into drug sales has hit a snag, and the retail giant has reportedly put at least one plan on ice. CNBC reports that Amazon Business—which sells bulk products to companies—can't convince hospitals to get on board, partly because the retail giant just doesn't have the required infrastructure. Wednesday, April 18, 2018 Merck & Co. has a big target in mind for its pneumococcal vaccine V114: no less than Prevnar 13, the world's best-selling shot. So, the U.S. drugmaker has charted a phase 3 course for V114 that includes a head-to-head trial against the Pfizer shot. Friday, April 13, 2018 Theranos CEO Elizabeth Holmes has warned investors that the company risks defaulting on a loan following delays to its Zika virus assay, BuzzFeed News reports. The embattled executive wants investors to save Theranos from the prospect of running dangerously low on cash by the end of July. Friday, April 13, 2018 An international team found that a personalized ovarian cancer vaccine was most effective when administered alongside a pair of approved cancer meds. Wednesday, April 18, 2018 Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina. Wednesday, April 18, 2018 St. Jude Children's Research Hospital, working with Microsoft and DNAnexus, has launched a new cloud platform to help researchers study genetic factors behind pediatric cancer. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Veeva Systems Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams. Sponsored by: Veeva Systems To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights. Sponsored by: Veeva Systems Explore a new model for events management, and learn how to deliver more value. Sponsored by: WCG Small biopharma companies are conducting almost 50% of the clinical trials in the US today, yet they face unique challenges that large pharma do not. In this paper, we explore some of those challenges, and solutions that can reduce the pressure on small biopharma teams and timelines. Sponsored by: Halo Pharma Why does confidence matter when outsourcing Fixed-Dose Combination products? Download Halo Pharma’s white paper on the importance of product design, technology, and analyticals tools for FDC. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
